New CDH3 Mutation in the First Spanish Case of Hypotrichosis with Juvenile Macular Dystrophy, a Case Report
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Ectodermal Dysplasias: a New Clinical-Genetic Classification
J Med Genet 2001;38:579–585 579 Ectodermal dysplasias: a new clinical-genetic J Med Genet: first published as 10.1136/jmg.38.9.579 on 1 September 2001. Downloaded from classification Manuela Priolo, Carmelo Laganà Abstract many case reports and personal communica- The ectodermal dysplasias (EDs) are a tions in their listing of EDs, as well as large and complex nosological group of conditions traditionally classified under other diseases, first described by Thurnam in headings, for example dyskeratosis congenita11 1848. In the last 10 years more than 170 and keratitis-ichthyosis-deafness (KID) syn- diVerent pathological clinical conditions drome12 (poikiloderma and immune defect have been recognised and defined as EDs, diseases and erythrokeratodermas, respec- all sharing in common anomalies of the tively). Further, they did not appear to hair, teeth, nails, and sweat glands. Many consider variability of expression and may are associated with anomalies in other have reported, as distinct diseases, conditions organs and systems and, in some condi- that reflect variable expression of the same tions, with mental retardation. pathological entity. Moreover, they included The anomalies aVecting the epidermis pathological conditions which, in our opinion, and epidermal appendages are extremely do not strictly fulfil the diagnostic criteria for variable and clinical overlap is present EDs, such as conditions with secondary among the majority of EDs. Most EDs are involvement of epidermal derivatives rather defined by particular clinical signs (for than a primary defect. We abandoned the 1-2- example, eyelid adhesion in AEC syn- 3-4 designation of EDs, because we believe drome, ectrodactyly in EEC). -
Absent Meibomian Glands: a Marker for Eecsyndrome
ABSENT MEIBOMIAN GLANDS: A MARKER FOR EECSYNDROME ELIZABETH BONNAR, PATRICIA LOGAN and PETER EUSTACE Dublin, Ireland SUMMARY watering eye for the previous week. He gave a A patient with a 20 year history of severe keratocon history of continuous attendance at eye clinics in junctivitis of unknown origin was found, on assessment various hospitals since the age of 3 years and was at a blepharitis clinic, to have complete absence of currently attending our own clinic, where he had last meibomian glands. Further examination revealed the been seen 1 month previously. Maintenance medica features of EEC syndrome. To our knowledge, this is tion was antiviral ointment and artificial tears. Old the only case to have been diagnosed in this way. The notes were unavailable on admission but there had ocular complications of EEC syndrome and other been a previous spontaneous perforation of the left ectodermal dysplasias are reviewed. cornea at the age of 15 years, and an operation for a blocked tear duct on the right side at the age of 8 The combination of ectrodactyly (lobster claw years. deformity of the hands and feet), ectodermal Vision was 6/18 on the right and hand movements dysplasia (abnormalities of hair, teeth, nails and on the left. There was marked photophobia and sweat glands) and cleft lip and palate, known as EEC tearing on both sides. The left cornea was opacified syndrome, is a rare multiple congenital abnormal and vascularised 360°, with central thinning and a ity.1,2 Fewer than 180 cases have been reported in the small perforation just inferonasal to the pupil (Fig. -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
Prevalence and Incidence of Rare Diseases: Bibliographic Data
Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct. -
Orphanet Report Series Rare Diseases Collection
Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic -
The Urothelial Cell Line Urotsa Transformed by Arsenite and Cadmium Display Basal Characteristics Associated with Muscle Invasive Urothelial Cancers
University of North Dakota UND Scholarly Commons Pathology Faculty Publications Department of Pathology 12-14-2018 The Urothelial Cell Line UROtsa Transformed by Arsenite and Cadmium Display Basal Characteristics Associated with Muscle Invasive Urothelial Cancers Zachary E. Hoggarth Danyelle B. Osowski Brooke A. Freeberg Scott H. Garrett University of North Dakota, [email protected] Mary Ann Sens University of North Dakota, [email protected] See next page for additional authors Follow this and additional works at: https://commons.und.edu/path-fac Recommended Citation Hoggarth, Zachary E.; Osowski, Danyelle B.; Freeberg, Brooke A.; Garrett, Scott H.; Sens, Mary Ann; Zhou, Xudong; Zhang, Ke K.; and Somji, Seema, "The Urothelial Cell Line UROtsa Transformed by Arsenite and Cadmium Display Basal Characteristics Associated with Muscle Invasive Urothelial Cancers" (2018). Pathology Faculty Publications. 1. https://commons.und.edu/path-fac/1 This Article is brought to you for free and open access by the Department of Pathology at UND Scholarly Commons. It has been accepted for inclusion in Pathology Faculty Publications by an authorized administrator of UND Scholarly Commons. For more information, please contact [email protected]. Authors Zachary E. Hoggarth, Danyelle B. Osowski, Brooke A. Freeberg, Scott H. Garrett, Mary Ann Sens, Xudong Zhou, Ke K. Zhang, and Seema Somji This article is available at UND Scholarly Commons: https://commons.und.edu/path-fac/1 RESEARCH ARTICLE The urothelial cell line UROtsa transformed by arsenite and cadmium display basal characteristics associated with muscle invasive urothelial cancers Zachary E. Hoggarth, Danyelle B. Osowski, Brooke A. Freeberg, Scott H. Garrett, Donald A. -
Adherens Junctions, Desmosomes and Tight Junctions in Epidermal Barrier Function Johanna M
14 The Open Dermatology Journal, 2010, 4, 14-20 Open Access Adherens Junctions, Desmosomes and Tight Junctions in Epidermal Barrier Function Johanna M. Brandner1,§, Marek Haftek*,2,§ and Carien M. Niessen3,§ 1Department of Dermatology and Venerology, University Hospital Hamburg-Eppendorf, Hamburg, Germany 2University of Lyon, EA4169 Normal and Pathological Functions of Skin Barrier, E. Herriot Hospital, Lyon, France 3Department of Dermatology, Center for Molecular Medicine, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Germany Abstract: The skin is an indispensable barrier which protects the body from the uncontrolled loss of water and solutes as well as from chemical and physical assaults and the invasion of pathogens. In recent years several studies have suggested an important role of intercellular junctions for the barrier function of the epidermis. In this review we summarize our knowledge of the impact of adherens junctions, (corneo)-desmosomes and tight junctions on barrier function of the skin. Keywords: Cadherins, catenins, claudins, cell polarity, stratum corneum, skin diseases. INTRODUCTION ADHERENS JUNCTIONS The stratifying epidermis of the skin physically separates Adherens junctions are intercellular structures that couple the organism from its environment and serves as its first line intercellular adhesion to the cytoskeleton thereby creating a of structural and functional defense against dehydration, transcellular network that coordinate the behavior of a chemical substances, physical insults and micro-organisms. population of cells. Adherens junctions are dynamic entities The living cell layers of the epidermis are crucial in the and also function as signal platforms that regulate formation and maintenance of the barrier on two different cytoskeletal dynamics and cell polarity. -
Coexisting Proinflammatory and Antioxidative Endothelial Transcription Profiles in a Disturbed Flow Region of the Adult Porcine Aorta
Coexisting proinflammatory and antioxidative endothelial transcription profiles in a disturbed flow region of the adult porcine aorta Anthony G. Passerini*†‡, Denise C. Polacek*‡, Congzhu Shi*, Nadeene M. Francesco*, Elisabetta Manduchi§, Gregory R. Grant§, William F. Pritchard¶, Steven Powellʈ, Gary Y. Chang*†, Christian J. Stoeckert, Jr.§**, and Peter F. Davies*†,††‡‡ *Institute for Medicine and Engineering, Departments of †Bioengineering, ††Pathology and Laboratory Medicine, and **Genetics, and §Center for Bioinformatics, University of Pennsylvania, Philadelphia, PA 19104; ¶U.S. Food and Drug Administration, Rockville, MD 20852; and ʈAstraZeneca Pharmaceuticals, Mereside Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom Edited by Louis J. Ignarro, University of California School of Medicine, Los Angeles, CA, and approved December 22, 2003 (received for review September 15, 2003) In the arterial circulation, regions of disturbed flow (DF), which are with protective profiles of gene expression (e.g., antioxidative, characterized by flow separation and transient vortices, are suscep- antiinflammatory, and͞or antiproliferative) when compared to the tible to atherogenesis, whereas regions of undisturbed laminar flow absence of flow (7–11, 13, 14, 17, 19) and selected examples of the (UF) appear protected. Coordinated regulation of gene expression by protective genes have been shown to be expressed in endothelium endothelial cells (EC) may result in differing regional phenotypes that in vivo (14, 19). A small number of microarray studies comparing either favor or inhibit atherogenesis. Linearly amplified RNA from EC gene expression between DF and UF conditions in vitro have freshly isolated EC of DF (inner aortic arch) and UF (descending been conducted (15, 16); however, transcriptional profiling in vivo thoracic aorta) regions of normal adult pigs was used to profile has been limited by the small sample size available within hemo- differential gene expression reflecting the steady state in vivo.By dynamic regions of interest. -
Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in -
Minimal 16Q Genomic Loss Implicates Cadherin-11 in Retinoblastoma
Minimal 16q Genomic Loss Implicates Cadherin-11 in Retinoblastoma Mellone N. Marchong,1,2 Danian Chen,1,6 Timothy W. Corson,1,3 Cheong Lee,1 Maria Harmandayan,1 Ella Bowles,1 Ning Chen,5 and Brenda L. Gallie1,2,3,4,5 1Divisions of Cancer Informatics and Cellular and Molecular Biology, Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada; Departments of 2Medical Biophysics, 3Molecular and Medical Genetics, and 4Ophthalmology, University of Toronto, Toronto, Ontario, Canada; 5Retinoblastoma Solutions, Toronto, Ontario, Canada; and 6Department of Ophthalmology, West China Hospital, Faculty of Medicine, Sichuan University, Chengdu, People’s Republic of China Abstract compared with normal adult human retina. Our analyses Retinoblastoma is initiated by loss of both RB1 alleles. implicate CDH11, but not CDH13, as a potential tumor Previous studies have shown that retinoblastoma suppressor gene in retinoblastoma. (Mol Cancer Res tumors also show further genomic gains and losses. We 2004;2(9):495–503) now define a 2.62 Mbp minimal region of genomic loss of chromosome 16q22, which is likely to contain tumor suppressor gene(s), in 76 retinoblastoma tumors, using Introduction loss of heterozygosity (30 of 76 tumors) and quantitative Retinoblastoma is the most common intraocular tumor in multiplex PCR (71 of 76 tumors). The sequence-tagged children. Mutations of both alleles (M1 and M2) of the RB1 site WI-5835 within intron 2 of the cadherin-11 (CDH11) gene at chromosome 13q14 are necessary (1) for retinoblastoma gene showed the highest frequency of loss (54%, 22 of tumor initiation but not sufficient for malignant transformation 41 samples tested). -
British Medical Association Tavistock Square London WC1
Journal of Medical Genetics February 1983 Vol 20 No 1 J Med Genet: first published as on 1 February 1983. Downloaded from Contents The genetic status of mothers of isolated cases of Duchenne muscular dystrophy R J M LANE, M ROBINOW, AND A D ROSES page 1 Huntington's chorea in South Wales: mutation, fertility, and genetic fitness D A WALKER, P S HARPER, R G NEWCOMBE, AND K DAVIES page 12 Investigation of malignant hyperthermia: analysis of skeletal muscle proteins from normal and halothane sensitive pigs by two dimensional gel electrophoresis P A LORKIN AND H LEHMANN page 18 Phenotypic variation in the familial atypical multiple mole-melanoma syndrome (FAMMM) H T LYNCH, R M FUSARO, W A ALBANO, J PESTER, W J KIMBERLING, AND J F LYNCH page 25 The effect of the acetylator phenotype on the metabolism of sulphasalazine in man A K AZAD KHAN, M NURAZZAMAN, AND S C TRUELOVE page 30 Acetylator phenotypes in Papua New Guinea R J A PENKETH, S F A GIBNEY, G T NURSE, AND D A HOPKINSON page 37 Immunological tolerance induced by in utero injection R D BARNES, B E POTTINGER, J MARSTON, P FLECKNELL, R H T WARD, S KALTER, AND R L HEBERLING page 41 Chromosome changes in Alzheimer's presenile dementia K E BUCKTON, L J WHALLEY, M LEE, AND J E CHRISTIE page 46 http://jmg.bmj.com/ Association of ectodermal dysplasia, ectrodactyly, and macular dystrophy: the EEM syndrome s OHDO, K HIRAYAMA, AND T TERAWAKI page 52 Consanguineous matings in the Egyptian population M HAFEZ, H EL-TAHAN, M AWADALLA, H EL-KHAYAT, A ABDEL-GAFAR, AND M GOHONEIM page 58 Dissection of the aorta in Turner's syndrome W H PRICE AND J WILSON page 61 on September 27, 2021 by guest. -
Mapping Transmembrane Binding Partners for E-Cadherin Ectodomains
Mapping transmembrane binding partners for E-cadherin ectodomains Omer Shafraza, Bin Xieb, Soichiro Yamadaa, and Sanjeevi Sivasankara,b,1 aDepartment of Biomedical Engineering, University of California, Davis, CA 95616; and bBiophysics Graduate Group, University of California, Davis, CA 95616 Edited by Barry Honig, Howard Hughes Medical Institute, Columbia University, New York, NY, and approved October 28, 2020 (received for review May 22, 2020) We combine proximity labeling and single molecule binding assays proteins that directly interact with a transmembrane bait would to discover transmembrane protein interactions in cells. We first be positioned in close proximity to both the bait’s ectodomain screen for candidate binding partners by tagging the extracellular and cytoplasmic regions. Consequently, if the proximity-based and cytoplasmic regions of a “bait” protein with BioID biotin ligase labeling enzyme was fused to both the bait’s extracellular and and identify proximal proteins that are biotin tagged on both their cytoplasmic regions, identifying transmembrane proteins that extracellular and intracellular regions. We then test direct binding are biotinylated in both regions would enable us to narrow interactions between proximal proteins and the bait, using single down the list of possible binding partners for subsequent AFM molecule atomic force microscope binding assays. Using this ap- binding measurements. Furthermore, an integrated extracellu- proach, we identify binding partners for the extracellular region lar and cytoplasmic BioID measurement would significantly of E-cadherin, an essential cell–cell adhesion protein. We show that increase the precision of the screen by dramatically reducing the desmosomal proteins desmoglein-2 and desmocollin-3, the focal the number of false positive hits.